This review article is intended to introduce the uninitiated clinician to the basic concepts, aims and early findings of the genetic epidemiology of hypertension. It separates the rare monogenic 'Mendelian' hypertensive disorders from the vast majority of patients with essential hypertension, which is a complex, polygenic, multifactorial disorder resulting from interaction of several genes with each other and with the environment. 
Hypertensive phenotypes
Essential hypertension results from the interaction of hereditary and environmental factors and is one of the leading causes of premature cardiovascular morbidity and mortality. Blood pressure levels are highly correlated among family members, a fact attributable to either common genetic background or shared environment and lifestyle habits, or both. Studies of familial aggregation and rates of concordance among monozygotic and dizygotic twins suggest that genes may contribute as much as 40% of the risk to this disorder. 1 High blood pressure, defined as systolic pressure у140 mm Hg and diastolic у90 mm Hg, is characterised by a high but variable prevalence rate of 15-25% among populations. 2 But blood pressure does not have a bimodal distribution into normal and abnormal groups. Rather, it is a quantitative trait with wide phenotypic variation and a continuous distribution, where an arbitrary cutoff line at some point of the Gaussian curve separates normal from abnormal. This indicates that hypertension is a complex trait, ie, a phenotype that does not follow the classic Mendelian rules of dominant or recessive inheritance attributable to a single gene locus. 3 More likely, it is a polygenic and multifactorial disorder, in which heritable anthropometric, clinical or biochemical characteristics; and some applications of genetic epidemiologic techniques, such as linkage and association studies of certain gene polymorphisms with hypertension using affected sibling pairs and large sibships or wide genomic screens comparing affected and unaffected populations. Although so far there is no genotypic variation proven to be causally related to essential hypertension, its intermediate phenotypes or any of its complications, it is hoped that new, more efficient methods of genetic analysis will yield clinically meaningful information.
the interaction of several genes with each other and with the environment result in different phenotypes.
Hypertension is often associated with insulin resistance ranging from borderline fasting hyperglycaemia/hyperinsulinaemia to clinically overt diabetes mellitus type II. The frequent coexistence of the two conditions has suggested a common aetiologic background. 4 If left untreated, hypertension results in target organ complications, such as congestive heart failure, stroke and renal failure, all of which can be prevented to various extents by optimal blood pressure control. Coronary artery disease is also a frequent complication of both hypertension and diabetes, but appears to be less preventable by optimal blood pressure control. 5 For these reasons, it is now accepted that arterial blood pressure elevation per se is only one of the factors contributing to target organ damage and does not consistently predict the occurrence or severity of hypertensive complications. In other words, hypertension is too broad a phenotype.
Over the years several efforts have been made to classify essential hypertensive 5 into subtypes or 'intermediate phenotypes,' ie, subgroups homogeneous for one or more traits that might have diagnostic or prognostic significance. Various clinical or biochemical characteristics have been chosen in an effort to better define patients at risk of complications. An early such effort was the classification into renin subgroups (ie, patients with high, normal or low plasma renin activity in relation to their blood pressure and state of sodium balance). It was shown in both retrospective and prospective surveys that high-renin patients are at increased risk of myocardial infarction, 6 ,7 a finding in agreement with the demonstration that excess angiotensin II of exogenous or endogenous origin can produce myocardial infarcts. 8, 9 A trait deemed to be useful for classification into subgroups that would enhance subsequent genetic analysis, should be pathogenically meaningful and show evidence of heritability. Because essential hypertension is a complex disorder, in which many different genes at various loci are likely to be involved, it is expected that phenotypically different subjects may present with different constellations of gene mutations. Thus, searching for underlying genetic causes might be more likely to be fruitful in subpopulations classified according to intermediate phenotypes. Presumably heritable clinical characteristics, that have been used to subdivide the hypertensive population, include obesity (defined by the body mass index), abdominal adiposity (defined by the waist-to-hip ratio), early onset of hypertension (eg, before age 50 years), excessive severity of hypertension (eg, requiring triple drug regimen), hyperresponsiveness to adrenergic stimuli, salt sensitivity, etc. Biochemical traits include elevated fasting glucose and insulin levels, elevated circulating levels of pressor hormones such as renin, catecholamines and vasopressin, altered characteristics of alphaadrenergic receptors, decreased activity of the kallikrein-kinin system, different hormonal responses to salt loading, etc. Several of these traits have been shown (or are predicted) to coexist in the same individual. For example, low-renin individuals are likely to have low kallikrein excretion and high circulating vasopressin. Other biochemical parameters, such as angiotensin-converting enzyme and angiotensinogen levels, lipid profile, etc, have also been reported to differ among hypertensive populations and possibly contribute to cardiovascular risk.
A common intermediate phenotype is the socalled metabolic syndrome X. This consists of a constellation of clinical and biochemical characteristics, including hypertension, abdominal adiposity ('apple shape'), hyperlipidaemia, hyperglycaemia and hyperinsulinaemia. 4 Each one of these characteristics is an independent coronary risk factor and their coexistence multiplies the risk. Although its prevalence increases with age, this syndrome appears to have a clear genetic component, as the coexistence of hypertension and diabetes is twice as common in African Americans and three times as common in Mexican Americans compared to whites. 10 
Hypertension in black people
The prevalence of essential hypertension in black people is at least twice that of whites. 2 It is characterised by an earlier onset, more severe course and increased susceptibility to some hypertensionrelated complications, such as left ventricular hypertrophy, stroke and end-stage renal disease in comparison to white hypertensives. [11] [12] [13] Although lack of optimal blood pressure control due to socioeconomic, dietary and behavioural factors may be partly responsible for these findings, it is felt that genetically determined characteristics play an equal or more important role. [11] [12] [13] [14] Differences in the biochemical and endocrine profiles of black hypertensives suggest different pathophysiologic mechanisms than in white hypertensives. 15 A prime example of such a biological difference is the increased frequency and magnitude of salt sensitivity (ie, magnitude of blood pressure rise in response to a sodium load), which is encountered in about three-quarters of hypertensive black patients. 16 Salt sensitivity is associated with diminished ability to excrete a sodium load, and hence tendency to retain salt, which is attributable to a variety of mechanisms, including alterations in cation transport across cell membranes, abnormal renal haemodynamics, and decreased generation of intrarenal natriuretic substances such as kinins, atrial natriuretic peptides, prostaglandins and dopamine. Black hypertensives also tend to exhibit differences in other endocrine characteristics, such as low plasma renin activity, higher levels of endothelin, 17 augmented alpha-adrenergic receptor reactivity, higher levels of plasma vasopressin (AVP) and accentuated hypotensive response to an antivasopressor AVP antagonist. 18 It has also been proposed, but not uniformly accepted, that black subjects have relative insulin resistance. 15 Of particular interest is the fact that some of these racial differences have been observed not only in black hypertensives but also in black normotensives compared to age and gender-matched Caucasians. For example, in a normotensive population, lower levels of urinary kallikrein were reported not only in black vs Caucasian adults 19 but also in children. 20 In fact, it is possible that low levels of kallikrein might be one reason for lack of a local renoprotective effect of kinins and increased propensity of black hypertensives to renal damage, even under good blood pressure control.
There is strong clinical evidence suggesting that, although salt-sensitivity tends to increase with age, it has a large heritable component. 21 The high prevalence of salt-sensitivity described in African Americans appears to be also present in native Africans, as suggested by clinical observations in South Africa (Dr Naiker, personal communication). At this time it is unknown which traits make black subjects more prone to hypertension and to hypertensive nephrosclerosis. If genetic studies could identify specific characteristics relevant to the pathogenesis of hypertension or its complications in this population, preventive treatments could be developed which address these characteristics (eg, enzymatic enhancement of renal kinin production in an effort to reduce the excessive rates of hypertension-related end-stage renal disease).
Molecular genetics of essential hypertension
Although rare pedigrees have been discovered which display Mendelian forms of hypertension, the essential hypertension encountered in over 95% of the hypertensive population is unlikely to be attributable to a single 'hypertension gene'. It is more likely that a number of genes, whose products participate in the pathophysiology of hypertension by influencing various biological factors, would account for the genetic variability of blood pressure levels. Such 'candidate genes' include those encoding for various components of the renin-angiotensin-aldosterone system, the kallikrein-kinin system, the cation-transport systems regulating flux across cell membranes, the sympathetic nervous system, various vasoactive autacoids, neurotransmitters, etc.
Animal models have provided valuable insights into the genetics of hypertension in humans. For example, in strains of Dahl-S and spontaneously hypertensive rats (believed to be the experimental counterpart of human essential hypertension), investigators have linked blood pressure to the genes for renin, angiotensin-converting enzyme (ACE) and atrial natriuretic peptide receptor. [22] [23] [24] [25] However, several linkage and association studies of the human renin and ACE loci have given negative results, [26] [27] [28] [29] [30] [31] except for one study in a black population, which found a possible association between blood pressure and a restriction fragment length polymorphism (RFLP) in the renin gene. 32 The SA gene has also shown some promise as a candidate gene for hypertension. This gene was first identified as a candidate for rat hypertension, as it showed hyperexpression in the kidneys of spontaneously hypertensive rats compared to the normotensive control strain. 33 Subsequent genetic analysis has shown that the SA genotype conveys a significant effect on blood pressure in rats and the SA gene was associated with hypertension in a study of Japanese hypertensive patients, 34 but not Caucasian hypertensives. 35 Likewise, a genetic mutation of the ␣-adducin gene (a substance involved in ion transport and signal transduction in cells) was found to be associated with hypertension in a strain of hypertensive rats 36 and in an Italian hypertensive population 37 but not in a Scottish population. 38 Linkage and association studies between variants of the angiotensinogen (AGT) gene and hypertension have produced contradictory results. [39] [40] [41] [42] [43] Linkage between polymorphism of the AGT gene and human hypertension was initially reported in several different geographically separated populations. [39] [40] Two specific variants in the AGT gene were found to correlate with higher circulating AGT levels and to be significantly associated with hypertension in one study that compared allele frequencies of hypertensives and normotensives from France and Utah, USA 39 and in another from Japan. 40 However, in a similar analysis of hypertensives and normotensives in the UK no association was found between either one of these AGT variants and hypertension. 41 Furthermore, a repeat analysis of pooled large numbers of subjects from several European populations failed to confirm the original findings. 42 In African Americans the frequency of the M235T variant was far greater than that of Caucasians but was not associated with hypertension. 43 Interestingly, this AGT variant was reported to be statistically associated with pre-eclampsia. 44 Another study found an association between a polymorphism of the angiotensin II receptor gene (AT 1 ) and hypertension, but failed to demonstrate linkage by sib-pair analysis. 45 Polymorphisms in the insulin receptor gene have also been associated with hypertension. 46 In a series of studies from Europe it was reported that genetic variants in the ACE gene are important in determining plasma concentrations of ACE. 47, 48 Subsequently, the same investigators observed that one of these variants (which is determined by a 287 bp deletion) was significantly more frequent in patients who had sustained a myocardial infarct; 49, 50 moreover, the association between high levels of ACE and coronary events was strongest in people who would otherwise be classified as low-risk by the usual clinical criteria. Another team of investigators found a higher frequency of homozygotes for the deletion-allele in subjects with cardiac hypertrophy, 51 which is itself an independent coronary risk factor. Even if these findings are verified in other populations, they would not indicate whether excess ACE is a causative factor or merely a marker of coronary risk, and, if causative, whether its effects are due to abundant formation of angiotensin II or to excessive degradation of bradykinin. 52 These data illustrate the problems with attributing a causal role to genetic variants identified via statistical analysis of affected versus normal populations. Various strategies are employed to further dissect these findings.
In recent years, a small subset of patients that used to be classified as essential hypertensives, have now been found to have familial hypertension with Mendelian patterns of inheritance, that is attributable to a specific single genetic mutation. The first such pedigree was a family with glucocorticoid-remediable hypertension, a rare type of mineralocorticoid excess caused by a chimaeric 11-␤-hydroxylase/aldosterone synthase gene. 53 Other such rare single gene mutations have been found to cause the syndrome of apparent mineralocorticoid excess, 54 Liddle's syndrome of pseudoaldosteronism, 55 Gordon's syndrome of pseudohypoaldosteronism 56 and a syndrome characterised by hypertension, short stature, brachydactyly and excessive propensity to strokes. 57 Additional such 'Mendelian pedigrees' may be discovered in the future, but so far they have not helped explain the mechanisms of essential hypertension. Indeed, several investigators have explored a possible role of mutations or variants of the epithelial sodium channel (similar to those causing Liddle's syndrome) in the pathogenesis of essential hypertension, but found no such evidence. 58, 59 What they did find was significant racial differences in the distribution of these variants 59, 60 which again underlines the risks of pooling populations from different genetic backgrounds. 3 In conclusion, so far there is no genotype proven to be causally related to essential hypertension or to one of its intermediate phenotypes. At most, it could be stated that some of the polymorphisms described above may confer increased susceptibility to hypertension or its complications in certain populations. Further progress is expected via continuing use of molecular genetic techniques, such as genomic screens for detection of additional polymorphisms in other candidate genes, identification of new genetic markers and systematic genetic mapping of spe-cific chromosomal regions. When the Human Genome project is completed, it is expected to provide a list of all genes located in each chromosomal region and hence further facilitate these efforts.
